IL-APTARGROUP
26.5.2021 14:32:09 CEST | Business Wire | Press release
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, announces the launch of the company’s first fully recyclable mono-material pump for the beauty and personal care industries, called Future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210526005198/en/
Certified and Sustainable by Design
In order to facilitate recycling, Future was designed using polyethylene (PE) mono-material only. Future is certified by Cyclos-HTP, the institute for Recyclability and Product Responsibility * . The innovation is also recognized “A” by RecyClass – a comprehensive cross-industry initiative that works to establish a harmonized recycling approach and traceability in Europe*.
“Today we are pleased to launch our latest sustainable innovation, Future, a game changing dispensing solution. Following more than two years of design, engineering and testing, I am very proud of our team’s mono-material design and it truly reflects our commitment to a more circular economy,” said Marc Prieur, President, Aptar Beauty + Home.
In developing the concept for Future, Aptar’s experts turned to recognized eco-design principles, which call for plastic dispensing products to be made from a mono-material to facilitate the recycling process. Traditional pumps may contain different materials, including metal components that can in some cases complicate the recycling process. Because the Future pump is made from PE only, it also aligns with the most common materials used to make bottles – PE and PET. Therefore, the complete packaging, including pump and bottle, are more easily recycled*.
Christophe Marie, Product Sustainability Director, Aptar, explains, “The ideal situation for the complete value chain is to have mono-material packaging where the container, the closure or dispensing system is made from the same material family. This was the big challenge our innovation team overcame with the development of Future.”
*Subject to local recyclability facilities and fully recyclable with PET and PE bottles.
RecyClass recognition applies for an undecorated clear or white pump.
Future is also available using post-consumer resin (PCR). Aptar Beauty + Home proudly obtained an International Sustainability & Carbon Certification (ISCC) for its European production.
“Our ultimate goal was to have the final consumer be able to take their body lotion, shampoo or shower gel and easily put the empty packaging in their recycling bin. This way, it enters a circular life cycle and can be turned into another product,” explained Sabine Bouillet-Lubot, Global Strategic Marketing Director, Aptar Beauty + Home.
E-Commerce Capable & Eco-Design
The Future pump combines the best eco-design principles with cutting-edge innovation. A stand-out feature of the Future pump’s innovative design is an incorporated on/off locking system and a 360° degree actuator. This modern take on closure design also renders Future compliant with the rigorous ISTA 6-Amazon protocol**. Designed for e-commerce, Future’s ISTA 6 compliance ensures that the pump withstands the risks associated with transport and distribution network pressures as well as necessitates less protective carton and paper packaging.
**Subject to final tests conducted by a brand’s bottle choice.
Sustainability at Aptar
Aptar believes that the packaging industry must move beyond the make, use, dispose behaviors of the past and actively work toward a circular economy. By circulating used plastic and packaging, we keep it in the economy and out of the environment. Therefore, reducing the quantity of plastic needed, using recycled materials and developing reuse models. Our vision is to design products and processes with people and the planet in mind and we are focusing our activities on three mains areas for sustainability: recycled materials, recyclability and reusability. Collaboration is essential to achieving a more circular economy, so we work with partners, suppliers and customers who share our vision. As a member of the Ellen MacArthur Foundation’s New Plastics Economy Global Commitment, this innovation highlights our pledge to reduce environmental impact and support the Foundation’s vision for a circular economy. We are working hard towards our 2025 goal to have all of our packaging 100% reusable, recyclable or compostable for our dispensing solutions for the beauty, personal care, home care and food and beverage markets.
Aptar to Present at the ChangeNow 2021 Global Summit
Aptar’s innovative dispensing solution will be introduced live at the ChangeNOW 2021 Global Summit on May 27th. As a proud supporting partner of ChangeNOW, Aptar’s Vice President of Global Sustainability, Beth Holland, will be a featured guest speaker during the circular economy panel discussion.
About Aptar
Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com .
This press release contains forward-looking statements. Expressions or future or conditional verbs such as “will” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005198/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength25.8.2026 00:40:00 CEST | Press release
Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by year-endOmlyclo® 300 mg strength available in both pre-filled syringe (PFS) and autoinjector (AI) presentationsMultiple dose strengths and device options broaden treatment flexibility for healthcare professionals Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.1 With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions. Following the European launch of Omlyclo® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other
Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press release
QTSP status allows for full control over the digital trust value chain from identity verification to qualified electronic signature (QES) issuance Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity ve
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
